Vera Therapeutics (NASDAQ:VERA) Shares Gap Up – Should You Buy?

Vera Therapeutics, Inc. (NASDAQ:VERA) shares gapped up before the market opened on Tuesday . The stock had previously closed at $34.05, but opened at $37.14. Vera Therapeutics shares last traded at $33.16, with a volume of 3,506,658 shares traded.

More Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Strong ORIGIN 3 results support TRUTAKNA. Vera reported that TRUTAKNA met all prespecified endpoints in the Phase 3 ORIGIN 3 trial for IgA nephropathy. At 52 weeks, the treatment preserved kidney function, with a placebo-adjusted eGFR benefit of 5.6 mL/min/1.73m². Through 104 weeks, the annualized eGFR slope benefit was 5.0 mL/min/1.73m² per year, while the composite risk of kidney disease progression fell 76% versus placebo. Vera kidney drug Trutakna shows strong final results in Phase 3 trial
• Positive Sentiment: Regulatory milestone is planned. Based on the final analysis, Vera plans to submit a supplemental Biologics License Application in the fourth quarter of 2026 seeking full FDA approval, potentially expanding TRUTAKNA beyond its current accelerated approval. Vera’s TRUTAKNA Shows Two-Year Kidney Protection; SBLA Planned Q4 2026
• Positive Sentiment: Early commercial demand is encouraging. Vera said it generated more than 350 patient start forms during TRUTAKNA’s first 10 weeks, with paid claims and initially favorable payer policies. The company also described the drug’s safety profile as generally comparable to placebo. Vera Therapeutics Announces TRUTAKNA ORIGIN 3 Results
• Neutral Sentiment: The stock reversed earlier gains and moved lower. The market’s muted response suggests investors may have already anticipated positive trial results or are waiting for detailed data and confirmation of commercial traction. Vera Stock Slides Despite Positive Phase 3 Results
• Negative Sentiment: Approval and safety risks remain. TRUTAKNA’s current indication is still subject to accelerated-approval requirements, so continued approval depends on verification of clinical benefit. Infections occurred in 32% of treated patients versus 28% for placebo, and local administration reactions were more common, creating potential adoption and monitoring concerns.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. The Goldman Sachs Group reiterated a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. TD Cowen upped their target price on shares of Vera Therapeutics from $73.00 to $78.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Guggenheim upped their target price on shares of Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. raised their target price on shares of Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, September 8th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $84.00 price target on shares of Vera Therapeutics in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.15.

Vera Therapeutics Stock Performance

The stock has a market capitalization of $2.40 billion, a P/E ratio of -5.69 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The company’s fifty day simple moving average is $34.99 and its two-hundred day simple moving average is $37.09.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period in the prior year, the firm posted ($1.20) EPS. As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -6.44 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $35.12, for a total transaction of $649,720.00. Following the completion of the sale, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at approximately $8,261,769.28. This trade represents a 7.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 83,250 shares of company stock worth $3,307,800. Company insiders own 15.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nykredit A S bought a new position in Vera Therapeutics during the 2nd quarter worth $97,000. Strs Ohio bought a new stake in shares of Vera Therapeutics in the first quarter valued at about $249,000. NINE MASTS CAPITAL Ltd bought a new stake in shares of Vera Therapeutics in the second quarter valued at about $405,000. PSP Research LLC acquired a new position in shares of Vera Therapeutics in the fourth quarter valued at about $506,000. Finally, Arizona State Retirement System grew its stake in shares of Vera Therapeutics by 12.3% in the second quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock valued at $507,000 after acquiring an additional 1,295 shares in the last quarter. 99.21% of the stock is owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.